Literature DB >> 6577011

Combined ultrastructural, histochemical, and autoradiographic study of osteosarcoma after preoperative chemotherapy according to the COSS 80 protocol.

E Grundmann, A Roessner, W Schlake, M Immenkamp, P Preusser, G Wüst, J Ritter, E Schnepper.   

Abstract

Twelve osteosarcomas treated according to the COSS 80 protocol (preoperative chemotherapy, resection) were studied by light and electron microscopic, histochemical, and autoradiographic methods. Evidence of regressive and necrotic changes was found in many tumor cells, but the alterations were unspecific. Viable tumor cells of high malignancy were also observed regularly, often at the S phase. As the tumor regression continued, a strong reaction of the mononuclear phagocyte system was manifested by the presence of macrophages and giant cells.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6577011     DOI: 10.1007/bf00625048

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  11 in total

1.  Studies on calcification. I. The effect of inhibition of enzyme activity on developing bone and dentin.

Authors:  M S BURSTONE; P H KEYES
Journal:  Am J Pathol       Date:  1957 Nov-Dec       Impact factor: 4.307

2.  Histochemical comparison of naphthol AS-phosphates for the demonstration of phosphatases.

Authors:  M S BURSTONE
Journal:  J Natl Cancer Inst       Date:  1958-03       Impact factor: 13.506

3.  Histochemical identification of T and B areas in paraffin-embedded lymphoid tissues by demonstration of alpha-naphthyl acetate esterase (ANAE) activity.

Authors:  W Schlake; E M Meyer; E Grundmann
Journal:  Pathol Res Pract       Date:  1978-10       Impact factor: 3.250

4.  Phosphates of the naphthol AS series in the quantitative determination of alkaline and acid phosphatase activities "in situ" studied in polyacrylamide membrane model systems and by cytospectrophotometry.

Authors:  Z Lojda; M Van der Ploeg; P Van Duijn
Journal:  Histochemie       Date:  1967

5.  Histological and biochemical considerations in the treatment of oral cancer with preoperative methotrexate infusion.

Authors:  J D Desprez; C L Kiehn; T J Krizek; H Damm
Journal:  Plast Reconstr Surg       Date:  1966-10       Impact factor: 4.730

6.  Tumor cell types in osteosarcoma as revealed by electron microscopy. Implications for histogenesis and subclassification.

Authors:  E Grundmann; A Roessner; M Immenkamp
Journal:  Virchows Arch B Cell Pathol Incl Mol Pathol       Date:  1981

7.  [Formation of giant cells in oral squamous cell carcinoma during bleomycin treatment: enzymehistochemical, electronmicroscopic and ultrahistochemical investigations (author's transl)].

Authors:  A Burkhardt; G Bommer; J O Gebbers; W J Höltje
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1976-02-16

8.  Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy en bloc resection, and prosthetic bone replacement.

Authors:  A G Huvos; G Rosen; R C Marcove
Journal:  Arch Pathol Lab Med       Date:  1977-01       Impact factor: 5.534

9.  [Combination chemotherapy in osteogenic sarcoma: the Memorial Sloan-Kettering cancer center experience (author's transl)].

Authors:  H Jürgens; G Rosen
Journal:  Klin Padiatr       Date:  1980-03       Impact factor: 1.349

10.  Comparative single-cell and flow DNA analysis of bone sarcoma.

Authors:  A Kreicbergs; G Cewrien; B Tribukait; A Zetterberg
Journal:  Anal Quant Cytol       Date:  1981-06
View more
  2 in total

1.  Cytostatic effects in osteosarcomas as detected by flow cytometric DNA analysis after preoperative chemotherapy according to the COSS 80/82 protocol.

Authors:  T Bösing; A Roessner; W Hiddemann; W Mellin; E Grundmann
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

2.  Morphology of pulmonary metastases from osteosarcoma during chemotherapy.

Authors:  T Derstappen; A Roessner; K M Müller; E Grundmann
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.